Advertisement

Topics

Latest "Sutent Drug Insights 2017 Updated 30052017 Prices from" News Stories

12:59 EDT 26th March 2019 | BioPortfolio

Here are the most relevant search results for "Sutent Drug Insights 2017 Updated 30052017 Prices from" found in our extensive news archives from over 250 global news sources.

More Information about Sutent Drug Insights 2017 Updated 30052017 Prices from on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Sutent Drug Insights 2017 Updated 30052017 Prices from for you to read. Along with our medical data and news we also list Sutent Drug Insights 2017 Updated 30052017 Prices from Clinical Trials, which are updated daily. BioPortfolio also has a large database of Sutent Drug Insights 2017 Updated 30052017 Prices from Companies for you to search.

Showing "Sutent Drug Insights 2017 Updated 30052017 Prices from" News Articles 1–25 of 37,000+

Tuesday 26th March 2019

Patients “increasingly worried” about drug supplies amid Brexit uncertainty, says royal college

Patients are “increasingly worried” by a lack of information around how drug supplies will be affected by Brexit, despite repeated government reassurances that access will not be impeded, the Royal...


Stretcher Chairs Global Market Research and Forecast, 20152025 [Report Updated: 01011970] Prices from USD $2200

SummaryThe Stretcher Chairs report provides an independent information about the Stretcher Chairs industry supported by extensive research on factors such as industry segmentssize trends, inhibitors, dynamics, drivers, opportunities challenges, environment policy, cost overview, porter's five force analysis, and key companies profiles including business overview and recent development.The rep...

NanoSurface Biomedical Launches New Drug Screening Platform with Structurally Matured Human Heart Tissues Derived from Stem Cells

NanoSurface Biomedical, a leading provider of biomimetic cell-based assay products and services, announced today the launch of the NanoSurface Car(ina)™ platform for highly predictive pre-clinical drug screening, using structurally matured human induced pluripotent stem cell (iPSC) derived heart tissues. This innovative human stem cell-based technology e...


Promedior Receives Breakthrough Therapy Designation from FDA for PRM-151 in Idiopathic Pulmonary Fibrosis

LEXINGTON, Mass., March 26, 2019 /PRNewswire/ — Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that PRM-151, a novel investigational anti-fibrotic immunomodulator, has been granted Breakthrough Therapy designation (BTD) by the U.S. Food and Drug Administration (FDA) for Idiopathic Pulmonary Fibrosis (IPF).&...

Tips to Design Successful Immuno-Oncology Efficacy Studies to Push Drug Discovery Further

Sponsored content brought to you by If you have ever screened a compound library and successfully killed tumor cells in a dish, you might be surprised to find that many of those compounds may have little or no effect when those same tumor cells are implanted in a mouse. Certainly, failing your lead compound sooner, […] The post Tips to Design Successful Immuno-Oncology Efficacy Studies to Pu...

Trump wants to work with Democrats on drug prices, infrastructure: aide

U.S. President Donald Trump is willing to work with congressional Democrats to lower drug prices for Americans and on infrastructure funding, White House adviser Kellyanne Conway said on Tuesday.

Aspirin a Day Keeps Tuberculosis Away?

While not quite as straight forward as the title would suggest, investigators at the Centenary Institute in Sydney did find that a brand-new target for treating drug-resistant tuberculosis is sensitive to anti-platelet drugs such as aspirin. Tuberculosis (TB) is still a major public health threat worldwide, with 10 million cases in 2017 and 1.3 million […] The post Aspirin a Day Keeps Tuberc...

Confirm BioSciences Secures Funding with HCAP Partners to Accelerate Global Expansion

New Investment to Fuel New Product Innovations and Strategic Growth SAN DIEGO (PRWEB) March 26, 2019 Confirm BioSciences, the San Diego, CA-based leader for high-quality diagnostic testing and health & wellness solutions for both the corporate community and individual consumers, today announced it has secured impact financing from HCAP Partners, a California-based private equity firm and reco...

Medrio Announces Multi-Year Enterprise Agreement with Deep Intelligent Pharma (DIP) for eSuite of Services

The collaboration will create additional value for pharma R&D clients globally including China, Japan, Australia, the United States, and EMEA. SAN FRANCISCO (PRWEB) March 26, 2019 Xing Li, The founder and CEO of Deep Intelligent Pharma (DIP), and Shinya Yamamoto, The Managing Director of Medrio, Inc., Asia-Pacific Region, announced a strategic alliance between DIP and Medrio at DIP’s Beijin...

Postpartum depression: new drug will be monitored at approved sites

The first drug approved by the US Food and Drug Administration for the treatment for postpartum depression will be administered only to short term inpatients at specially approved sites, as the FDA...

EU approves AZ' Forxiga for type I diabetes

The drug is the first oral medicine approved in Europe as an adjunct to insulin for adults with type I diabetes.

Tiziana submits IND for Foralumab oral formulation in NASH

Tiziana has submitted an Investigational New Drug application for an oral formulation of Foralumab.

McKesson ideaShare Unites Independent Pharmacy

Premier community pharmacy education and networking event hits Orlando in 2019 Registration is now open for McKesson ideaShare in Orlando from June 26–30, 2019. Pharmacists, pharmacy owners and pharmacy technicians have the chance to

Applications of nanotech may provide bioavailability

Nanotechnology may be able to increase bioavailability in low-solubility drugs and improve a drugâs chance of success, according to Ascendia CEO.

Purdue Pharma, maker of OxyContin, settles opioids lawsuit in Oklahoma

Oklahoma officials were set to announce a settlement with Purdue Pharma in a major lawsuit accusing drug makers of fueling opioid the epidemic. 

Vivior’s System Cleared for CE Mark – Market Introduction This Year in Europe

Vivior has cleared their system as a Class I medical device and is planning the market introduction later this year in Switzerland and the European Union. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190326005594/en/ The Visual Behavior

Catalent Biologics to Present on Tech Transfer, Biomanufacturing and Aseptic Processing at INTERPHEX

Catalent Pharma Solutions (Booth 1145), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that two of its manufacturing experts will present at the INTERPHEX Conference and Exhibition, taking place at the Javits Center, New York City, on April 2-4, 2019. SOMERSET, N.J. (PRWEB) March 26, 2019 C...

Chamberlain University Names Dr. Simendea Clark President of Chicago Campus

Chamberlain University announced today that Dr. Simendea Clark, DNP, RN has been appointed president of its Chicago campus, one of three Chicagoland campuses. Dr. Clark is responsible for the Chicago campus nursing program and operations, including overall academic excellence, student services, support and success. Since joining Chamberlain in 201...

Covetrus Announces Appointment of Matthew Leonard as Executive Vice President, President North America and Global Supply Chain Officer

Leonard Brings Significant Expertise in Technology, Procurement and Supply Chain Covetrus (NASDAQ: CVET), a global leader in animal-health technology and services, announced today that Matthew Leonard has been named Executive Vice President, President North America and Global Supply Chain Officer effective April 8, 2019. In his role, Leonard will ...

Shaolian Zhou, Ph.D., Joins Worldwide Clinical Trials as Senior Vice President and Lab Director for Bioanalytical Services

Worldwide Clinical Trials, Inc. (Worldwide), an award-winning, full-service, midsize, global CRO, announced today that Shaolian Zhou, Ph.D., has joined the company as senior vice president and lab director for Bioanalytical Services. Based at the company’s Austin, Texas, Bioanalytic Laboratory, Dr. Zhou is responsible for the overall operations of...

Collective Medical Appoints Jim Lacy as President and Chief Operating Officer

Lacy to apply his proven approach to strategy, policy and product to accelerate rapid growth toward connecting the healthcare system at scale Collective Medical, delivering the nation’s largest and most effective network for care collaboration, today announced the appointment of Jim Lacy as president and chief operating officer. This press rele...

Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection

– In Clinical Trials, Biktarvy Demonstrated High Efficacy, Few Interactions with Other Drugs and a High Barrier to Resistance Through 48 Weeks – Gilead Sciences, Inc. (NASDAQ:GILD) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Biktarvy® (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, ...

Aimmune’s peanut allergy drug meets primary endpoint in Phase III trial

Food allergy-focused Aimmune Therapeutics has announced its peanut allergy drug AR101 met its primary endpoint in Phase III European clinical...Read More... The post Aimmune’s peanut allergy drug meets primary endpoint in Phase III trial appeared first on Pharmaceutical Technology.

Lipella Pharmaceuticals Received FDA IND Approval for Phase-2a Oncology Supportive Care Drug Study

LP-10, which has received FDA Orphan Drug designation, has now obtained IND approval for Phase-2a, multi-center, double-blind, controlled, clinical trial for hemorrhagic cystitis. Lipella Pharmaceuticals Inc., a clinical stage biopharmaceutical company based in Pittsburgh, PA, anno

ReviveMed Receives Frost & Sullivan AI-Driven Next-Generation Metabolomics Technology Innovation Award

ReviveMed is proud to announce that they are the recipient of the North American AI-Driven Next-Generation Metabolomics Technology Innovation Award from Frost & Sullivan as part of that company's 2018 Best Practices Awards. Frost & Sullivan, which has been providing a wide range of business consulting and market research analysis for over 50 years,...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks